Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Cash from Financing Activities: 2022-2025

Historic Cash from Financing Activities for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to $8,000.

  • Entrada Therapeutics' Cash from Financing Activities rose 172.73% to $8,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 97.95%. This contributed to the annual value of $103.0 million for FY2024, which is 389.44% up from last year.
  • As of Q3 2025, Entrada Therapeutics' Cash from Financing Activities stood at $8,000, which was down 97.63% from $337,000 recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Cash from Financing Activities ranged from a high of $101.4 million in Q2 2024 and a low of -$11,000 during Q3 2024.
  • Over the past 3 years, Entrada Therapeutics' median Cash from Financing Activities value was $368,000 (recorded in 2023), while the average stood at $11.3 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first soared by 38,972.00% in 2023, then slumped by 102.99% in 2024.
  • Entrada Therapeutics' Cash from Financing Activities (Quarterly) stood at $358,000 in 2022, then surged by 92.74% to $690,000 in 2023, then soared by 103.19% to $1.4 million in 2024, then spiked by 172.73% to $8,000 in 2025.
  • Its last three reported values are $8,000 in Q3 2025, $337,000 for Q2 2025, and $350,000 during Q1 2025.